COLO Stock Overview
Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
Coloplast A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 119.40 |
| 52 Week High | DKK 130.90 |
| 52 Week Low | DKK 99.26 |
| Beta | 0.34 |
| 11 Month Change | -0.67% |
| 3 Month Change | -0.21% |
| 1 Year Change | 18.69% |
| 33 Year Change | -25.02% |
| 5 Year Change | 11.64% |
| Change since IPO | 77.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| COLO | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | -4.7% | -2.4% | 0.9% |
| 1Y | 18.7% | 13.2% | 1.5% |
Return vs Industry: COLO exceeded the Austrian Medical Equipment industry which returned 13.2% over the past year.
Return vs Market: COLO exceeded the Austrian Market which returned 1.5% over the past year.
Price Volatility
| COLO volatility | |
|---|---|
| COLO Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.3% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: COLO has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: COLO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 16,639 | Kristian Villumsen | www.coloplast.com |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
Coloplast A/S Fundamentals Summary
| COLO fundamental statistics | |
|---|---|
| Market cap | €26.86b |
| Earnings (TTM) | €677.26m |
| Revenue (TTM) | €3.62b |
39.7x
P/E Ratio7.4x
P/S RatioIs COLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLO income statement (TTM) | |
|---|---|
| Revenue | DKK 27.03b |
| Cost of Revenue | DKK 8.76b |
| Gross Profit | DKK 18.27b |
| Other Expenses | DKK 13.22b |
| Earnings | DKK 5.05b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 04, 2025
| Earnings per share (EPS) | 22.44 |
| Gross Margin | 67.59% |
| Net Profit Margin | 18.69% |
| Debt/Equity Ratio | 120.6% |
How did COLO perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield98%
Payout RatioDoes COLO pay a reliable dividends?
See COLO dividend history and benchmarks| Coloplast dividend dates | |
|---|---|
| Ex Dividend Date | Dec 06 2024 |
| Dividend Pay Date | Dec 10 2024 |
| Days until Ex dividend | 17 days |
| Days until Dividend pay date | 21 days |
Does COLO pay a reliable dividends?
See COLO dividend history and benchmarks